G6PD Deficiency and Pharmacogenetics

G6PD deficiency is an X-linked recessive hereditary enzymopathy affecting an estimated 400 to 500 million people globally, making it the most prevalent human enzyme defect. Caused by missense variants in the housekeeping G6PD gene on the distal long arm of the X chromosome (Xq28), the disorder reduces the catalytic stability and activity of glucose-6-phosphate dehydrogenase (G6PD)—the rate-limiting initial enzyme of the oxidative pentose phosphate pathway.

Under baseline physiological conditions, most individuals with G6PD deficiency remain asymptomatic throughout life. However, because mature anucleate erythrocytes lack mitochondria, ribosomes, and a nucleus, they cannot synthesize replacement enzyme proteins and depend on the pentose phosphate pathway as their only source of reduced nicotinamide adenine dinucleotide phosphate (NADPH). When G6PD-deficient red blood cells are challenged by exogenous redox-cycling drugs (such as primaquine, tafenoquine, dapsone, or rasburicase), acute bacterial or viral infections, or the ingestion of fava beans (Vicia faba), intracellular NADPH and reduced glutathione (GSH) reserves collapse, precipitating acute oxidative hemolytic anemia, methemoglobinemia, and neonatal hyperbilirubinemia.

The Pentose Phosphate Pathway and Glutathione Peroxidase Antioxidant Defense

In all mammalian cells, cytosolic G6PD (active as a homodimer or homotetramer requiring a tightly bound structural NADP⁺ molecule per monomer for conformational stability) catalyzes the oxidation of D-glucose-6-phosphate to 6-phospho-D-glucono-1,5-lactone while reducing NADP⁺ to NADPH:

D-Glucose-6-phosphate + NADP⁺ → 6-Phospho-D-glucono-1,5-lactone + NADPH + H⁺

Subsequent oxidation of 6-phosphogluconate by 6-phosphogluconate dehydrogenase generates a second molecule of NADPH per glucose-6-phosphate molecule entering the shunt.

In mature erythrocytes—which carry high concentrations of molecular oxygen (O₂) bound to ferrous heme (Fe²⁺) and continuously generate superoxide radicals (O₂^•−) and hydrogen peroxide (H₂O₂) via spontaneous hemoglobin autoxidation—NADPH serves two essential antioxidant functions:

1. Glutathione Recycling: The selenoenzyme glutathione peroxidase (GPx) detoxifies hydrogen peroxide and lipid hydroperoxides by coupling their reduction to the oxidation of two molecules of monomeric reduced glutathione (GSH) into glutathione disulfide (GSSG):

H₂O₂ + 2 GSH → GSSG + 2 H₂O

To sustain this defense, the FAD-dependent flavoenzyme glutathione reductase (GSR) continuously regenerates 2 GSH from GSSG using NADPH as the obligatory electron donor:

GSSG + NADPH + H⁺ → 2 GSH + NADP⁺

1. Catalase Stabilization and Methemoglobin Reduction: Erythrocytic catalase (which dismutates H₂O₂ into H₂O and O₂) requires tightly bound NADPH at an allosteric cofactor site to prevent suicide inactivation into compound II, while NADPH-dependent methemoglobin reductase serves as the secondary pathway illuminated by pharmacological electron carriers such as methylene blue.

During normal 120-day erythrocyte senescence, wild-type G6PD activity decays exponentially with a biological half-life of approximately 60 days, leaving reticulocytes with high enzymatic activity and aged red cells with ~50% residual activity. Pathogenic G6PD missense mutations accelerate this proteolytic decay: in the G6PD A− variant (t_1/2 ≈ 13 days), young reticulocytes retain near-normal G6PD activity while older erythrocytes are depleted, whereas in the G6PD Mediterranean variant (t_1/2 < 1 day), even newly released reticulocytes lack functional enzyme.

Heinz Body Formation, Bite Cells, and Intravascular/Extravascular Hemolysis

When a G6PD-deficient individual is exposed to an oxidative stressor—such as the hydroxylated metabolites of primaquine, the uricolytic enzyme rasburicase (which generates stoichiometric H₂O₂ during uric acid oxidation to allantoin), or the fava bean β-glucosides vicine and convicine (hydrolyzed in the gut to the redox-active pyrimidine aglycones divicine and isouramil)—erythrocyte NADPH and GSH are rapidly exhausted. Unchecked H₂O₂ and reactive oxygen species inflict three structural injuries on the red blood cell:

1. Heinz Body Precipitation: Oxidation of exposed sulfhydryl (–SH) groups on hemoglobin β-globin Cys93 and disulfide cross-linking of denatured globin chains produce insoluble, membrane-bound aggregates termed Heinz bodies (visualized by supravital staining with crystal violet or brilliant cresyl blue).
2. Bite and Blister Cells (Extravascular Hemolysis): As rigid erythrocytes containing Heinz bodies traverse the narrow interendothelial slits of the splenic cords, residential splenic macrophages ("pitting" macrophages) phagocytose the Heinz bodies together with a portion of the overlying plasma membrane, leaving characteristic bite cells (degmacytes) and blister cells on the peripheral blood smear.
3. Lipid Peroxidation and Methemoglobinemia (Intravascular Hemolysis): Peroxidation of spectrin and membrane phospholipids causes direct intravascular osmotic lysis, releasing free plasma hemoglobin (scavenged by haptoglobin until depleted), causing dark "cola-colored" hemoglobinuria, elevated serum lactate dehydrogenase (LDH) and unconjugated bilirubin, and oxidation of heme Fe²⁺ to ferric methemoglobin (Fe³⁺).

The Updated WHO 2022 Classification and Canonical G6PD Alleles

Because complete loss of G6PD is embryonic lethal in humans, all >230 known clinical G6PD variants are missense mutations or small in-frame deletions that preserve partial residual activity. In 2022, the World Health Organization (WHO) revised the classical 1967–1985 Yoshida Class I–V system (merging the former Class II [<10% activity] and Class III [10–60% activity] into a single acute-hemolysis category because both carry clinical risk with oxidative drugs):

Malaria Hypothesis and X-Chromosome Inactivation (Lyonization)

The global geographic distribution of Class B G6PD deficiency correlates closely with historical endemicity of Plasmodium falciparum and Plasmodium vivax malaria—a classic example of evolutionary balancing selection. Ring-stage malaria parasites infecting G6PD-deficient erythrocytes induce early oxidative stress and membrane senescence, triggering rapid splenic phagocytosis of parasitized red blood cells before the parasite can mature into schizonts.

Because G6PD is X-linked, hemizygous males (X⁻Y) and homozygous females (X⁻X⁻) have uniform erythrocyte deficiency. In contrast, heterozygous females (X⁺X⁻) undergo random embryonic X-chromosome inactivation (lyonization), producing a dual mosaic population of normal erythrocytes and G6PD-deficient erythrocytes in peripheral blood. Depending on the stochastic skewing of X-inactivation in hematopoietic stem cells, a heterozygous female's total blood G6PD enzymatic activity can range from 20% (phenotypically deficient) to 80% (phenotypically normal), which cannot be predicted by DNA genotyping alone and requires quantitative spectrophotometric G6PD activity testing (expressed in IU/g Hb).

The Clinical Pharmacogenetics Implementation Consortium (CPIC) stratifies medications into High Risk (avoid in Class A and Class B G6PD deficiency), Medium Risk (use with caution at standard doses), and Low-to-No Risk:

1. Rasburicase and Pegloticase (Recombinant Uricases): Used for tumor lysis syndrome and refractory gout, these enzymes oxidize uric acid to 5-hydroxyisourate and allantoin while producing stoichiometric H₂O₂. Both carry FDA Boxed Warnings and are contraindicated in G6PD deficiency (substitute allopurinol or febuxostat).
2. 8-Aminoquinoline Antimalarials (Primaquine and Tafenoquine): Required for radical cure (hypnozoite eradication) of Plasmodium vivax and Plasmodium ovale. Single-dose tafenoquine (300 mg, t_1/2 ≈ 15 days) is contraindicated if G6PD activity is <70% of normal (requiring quantitative phenotypic testing prior to administration). For primaquine, standard 14-day daily therapy (0.25–0.5 mg/kg/day) is contraindicated in Class A (<20%) and marked Class B deficiency; in mild-to-moderate Class B deficiency (such as G6PD A− with 10–30% activity), a modified WHO regimen of 0.75 mg/kg once weekly for 8 weeks takes advantage of compensatory reticulocytosis after the first dose.
3. Dapsone, Nitrofurantoin, and Sulfonylureas: The sulfone antibiotic dapsone and urinary antiseptic nitrofurantoin are high-risk hemolytic triggers and should be avoided in G6PD-deficient patients.
4. Methylene Blue (Methylthioninium Chloride): Standard antidote for acquired methemoglobinemia, methylene blue is contraindicated in G6PD deficiency.

Why is methylene blue contraindicated for treating methemoglobinemia in a patient with G6PD deficiency?

Pharmacological methylene blue acts as an artificial electron acceptor that must first be reduced inside erythrocytes to leucomethylene blue by NADPH-dependent methemoglobin reductase before leucomethylene blue can non-enzymatically reduce ferric methemoglobin (Fe³⁺) back to ferrous hemoglobin (Fe²⁺). Because G6PD-deficient erythrocytes lack NADPH, they cannot reduce methylene blue to leucomethylene blue; instead, unreduced methylene blue acts as a pro-oxidant that steals remaining electrons, worsening both methemoglobinemia and acute intravascular hemolysis. High-dose ascorbic acid (vitamin C) or hyperbaric oxygen / exchange transfusion is used instead.

Why can a quantitative G6PD enzyme assay yield a false-normal result soon after an acute hemolytic crisis?

In variants such as G6PD A−, young reticulocytes released from the bone marrow possess 5-fold higher G6PD catalytic activity than mature senescent erythrocytes. During an acute hemolytic episode, the oldest, most G6PD-depleted erythrocytes are selectively lysed first, while the bone marrow mounts a brisk reticulocytosis (raising reticulocyte counts to 10–20%). Measuring enzymatic activity during or soon after hemolysis assays this surviving reticulocyte-enriched cohort and can yield a falsely normal result; molecular genotyping or repeat enzymatic testing 8 to 12 weeks after recovery provides an accurate baseline diagnosis.

Why is quantitative enzymatic testing required in females before prescribing tafenoquine?

Because tafenoquine has a 15-day elimination half-life and cannot be withdrawn once a single 300-mg oral dose is ingested, patients with intermediate G6PD activity (<70% of normal median) can experience prolonged hemolysis. Qualitative rapid fluorescent spot tests reliably detect marked deficiency (<30% activity in hemizygous males) but miss heterozygous females with intermediate activity (30% to 70% activity due to X-chromosome lyonization), making quantitative spectrophotometric or point-of-care biosensor testing mandatory before prescribing tafenoquine.

1. Luzzatto, L., Ally, M., & Notaro, R. (2020). "Glucose-6-phosphate dehydrogenase deficiency." Blood, 136(11), 1225–1240. https://doi.org/10.1182/blood.2019000944
2. Gammal, R. S., Pirmohamed, M., Somogyi, A. A., Morris, S. A., Formea, C. M., Elchynski, A. L., et al. (2023). "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for medication use in the context of G6PD genotype." Clinical Pharmacology & Therapeutics, 113(5), 973–985. https://doi.org/10.1002/cpt.2735
3. Cappellini, M. D., & Fiorelli, G. (2008). "Glucose-6-phosphate dehydrogenase deficiency." The Lancet, 371(9606), 64–74. https://doi.org/10.1016/S0140-6736(08)60073-260073-2)
4. Beutler, E. (1994). "G6PD deficiency." Blood, 84(11), 3613–3636. https://doi.org/10.1182/blood.V84.11.3613.bloodjournal84113613